Loading...
Market
Outcome of AstraZeneca's insurance fraud investigation in China by end of 2025?
2
Resolution / Starting Odds
No charges filed • 25%
Fines imposed • 25%
Executives prosecuted • 25%
Other • 25%
Official statements from Chinese authorities or AstraZeneca
Story
AstraZeneca Faces Investigation in China Over Insurance Fraud Involving Tagrisso and Leon Wang
Nov 5, 2024, 10:00 AM
AstraZeneca is under investigation in China, with high-ranking executive Leon Wang and other personnel being scrutinized by authorities. The investigation stems from allegations that AstraZeneca China's sales team falsified genetic test results to ensure state-backed insurance would cover the company's lung cancer drug, Tagrisso. This insurance fraud has reportedly involved dozens of senior executives within the company and has led to prosecutions, as reported by Caixin Global. AstraZeneca's Chinese market, which accounts for approximately 13% of its $5.8 billion in revenue, is now facing significant challenges due to these allegations. Wang Lei, the executive vice president overseeing AstraZeneca’s operations in China, is cooperating with the authorities, though the details of the investigation remain unclear.
View original story
Similar markets
Upheld • 25%
Overturned • 25%
Settled • 25%
Other • 25%
No wrongdoing found • 25%
Minor violations found • 25%
Major violations found • 25%
Undetermined outcome • 25%
Yes • 50%
No • 50%
Resolved as planned • 25%
Resolved for more than $70 million • 25%
Resolved for less than $70 million • 25%
Not resolved • 25%
Guilty on all charges • 25%
Guilty on some charges • 25%
Not guilty • 25%
Case dismissed • 25%
Increase investment in China • 25%
Reduce operations in China • 25%
No change in strategy • 25%
Other strategic response • 25%
Stock price increases by more than 10% • 25%
Stock price increases by 5-10% • 25%
Stock price remains within +/- 5% • 25%
Stock price decreases by more than 5% • 25%
Convicted • 25%
Acquitted • 25%
Charges dropped • 25%
Awaiting trial • 25%
Patent infringement lawsuit • 25%
Settlement agreement • 25%
Licensing agreement • 25%
No major legal action • 25%
Less than 200 • 25%
200 to 300 • 25%
301 to 400 • 25%
More than 400 • 25%
No action taken • 33%
State Farm fined • 33%
State Farm's rate hike approved • 33%